Title:
ANALYTICAL METHOD FOR INCREASING SUSCEPTIBILITY OF MOLECULAR TARGETED THERAPY IN HEPATOCELLULAR CARCINOMA
Document Type and Number:
WIPO Patent Application WO/2014/175593
Kind Code:
A1
Abstract:
The present invention provides an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment. It has been found by the present invention that FGFR1 has relationship with susceptibility to sorafenib treatment. Therefore, the analysis on the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFRβ, c-KIT, c-RAF, EGFR, and/or mTOR) makes it possible to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.
Inventors:
PARK JIN-YOUNG (KR)
MOON YOUNG-HO (KR)
KWON JUNG-HEE (KR)
MOON YOUNG-HO (KR)
KWON JUNG-HEE (KR)
Application Number:
PCT/KR2014/003281
Publication Date:
October 30, 2014
Filing Date:
April 16, 2014
Export Citation:
Assignee:
CBS BIOSCIENCE CO LTD (KR)
International Classes:
G01N33/574; C12N15/11; C12Q1/68
Foreign References:
US20110257035A1 | 2011-10-20 | |||
US20070037224A1 | 2007-02-15 | |||
US20080311604A1 | 2008-12-18 | |||
US20110257035A1 | 2011-10-20 |
Other References:
TAI, W.-T. ET AL.: "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma", JOURNAL OF HEPATOLOGY, vol. 55, 2011, pages 1041 - 1048, XP028319540
WILHELM, S. M. ET AL.: "Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling", MOLECULAR CANCER THERAPEUTICS, vol. 7, no. 10, 2008, pages 3129 - 3140, XP055030698
YANG JD ET AL., NAT REV GASTROENTEROL HEPATOL, vol. 7, no. 314, 2010, pages 448 - 458
VILLANUEVA A ET AL., GASTROENTEROLOGY, vol. 140, no. 316, 2011, pages 1410 - 1426
LLOVET JM ET AL., N ENGL J MED, vol. 359, 2008, pages 378 - 390
CHENG AL ET AL., LANCET ONCOL, vol. 10, 2009, pages 25 - 34
ZHU AX, SEMIN ONCOL, vol. 39, 2012, pages 493 - 502
HUYNH H, BIOCHEM PHARMACOL, vol. 80, 2010, pages 550 - 560
VILLANUEVA A ET AL., CLIN CANCER RES, vol. 18, 2012, pages 1824 - 1826
VOGEL CL ET AL., J CLIN ONCOL, vol. 20, 2002, pages 719 - 726
LYNCH TJ ET AL., N ENGL J MED, vol. 350, pages 2129 - 2139
WEST L ET AL., PLOS ONE, vol. 7, pages e31906
VIDWANS SJ ET AL., PLOS ONE, vol. 6, pages e18257
J. CLIN. ONCOL., vol. 24, no. 26, 2006, pages 4293 - 4300
LLOVET JM ET AL.: "Sorafenib in advanced hepatocellular carcinoma", N ENGL J MED, vol. 359, 2008, pages 378 - 390, XP009185548, DOI: doi:10.1056/NEJMoa0708857
FORNER A ET AL., SEMIN LIVER DIS, vol. 30, no. 61-74, 2010, pages 346
EDMONDSON HA ET AL., CANCER, vol. 7, 1954, pages 462 - 503
KWON JH ET AL., CLIN CANCER RES, vol. 16, no. 350, 2010, pages 5511 - 5521
See also references of EP 2989466A4
WILHELM, S. M. ET AL.: "Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling", MOLECULAR CANCER THERAPEUTICS, vol. 7, no. 10, 2008, pages 3129 - 3140, XP055030698
YANG JD ET AL., NAT REV GASTROENTEROL HEPATOL, vol. 7, no. 314, 2010, pages 448 - 458
VILLANUEVA A ET AL., GASTROENTEROLOGY, vol. 140, no. 316, 2011, pages 1410 - 1426
LLOVET JM ET AL., N ENGL J MED, vol. 359, 2008, pages 378 - 390
CHENG AL ET AL., LANCET ONCOL, vol. 10, 2009, pages 25 - 34
ZHU AX, SEMIN ONCOL, vol. 39, 2012, pages 493 - 502
HUYNH H, BIOCHEM PHARMACOL, vol. 80, 2010, pages 550 - 560
VILLANUEVA A ET AL., CLIN CANCER RES, vol. 18, 2012, pages 1824 - 1826
VOGEL CL ET AL., J CLIN ONCOL, vol. 20, 2002, pages 719 - 726
LYNCH TJ ET AL., N ENGL J MED, vol. 350, pages 2129 - 2139
WEST L ET AL., PLOS ONE, vol. 7, pages e31906
VIDWANS SJ ET AL., PLOS ONE, vol. 6, pages e18257
J. CLIN. ONCOL., vol. 24, no. 26, 2006, pages 4293 - 4300
LLOVET JM ET AL.: "Sorafenib in advanced hepatocellular carcinoma", N ENGL J MED, vol. 359, 2008, pages 378 - 390, XP009185548, DOI: doi:10.1056/NEJMoa0708857
FORNER A ET AL., SEMIN LIVER DIS, vol. 30, no. 61-74, 2010, pages 346
EDMONDSON HA ET AL., CANCER, vol. 7, 1954, pages 462 - 503
KWON JH ET AL., CLIN CANCER RES, vol. 16, no. 350, 2010, pages 5511 - 5521
See also references of EP 2989466A4
Attorney, Agent or Firm:
OH, Kook-Jin (24 Beobwon-ro 3-gil,Seocho-gu, Seoul 137-884, KR)
Download PDF: